The National Institute of Health and Care Excellence (NICE) has recommended the use of Zejula (niraparib) as a maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The medication will be available through the Cancer Drugs Fund (CDF), a funding program that seeks to increase access to promising cancer medicines in England for patients with or without BRCA-mutated tumors who are responding to their initial round of platinum-based chemotherapy. NICE’s recommendation might…
You must be logged in to read/download the full post.
The post Zejula Now Available in UK as Maintenance Therapy for Advanced Ovarian Cancer appeared first on BioNewsFeeds.